CA2151927A1 - Cathepsine d, protease amyloidogene dans la maladie d'alzheimer - Google Patents
Cathepsine d, protease amyloidogene dans la maladie d'alzheimerInfo
- Publication number
- CA2151927A1 CA2151927A1 CA002151927A CA2151927A CA2151927A1 CA 2151927 A1 CA2151927 A1 CA 2151927A1 CA 002151927 A CA002151927 A CA 002151927A CA 2151927 A CA2151927 A CA 2151927A CA 2151927 A1 CA2151927 A1 CA 2151927A1
- Authority
- CA
- Canada
- Prior art keywords
- app
- cathepsin
- amyloid
- inhibitor
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8142—Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99566092A | 1992-12-16 | 1992-12-16 | |
US995,660 | 1992-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2151927A1 true CA2151927A1 (fr) | 1994-06-23 |
Family
ID=25542079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002151927A Abandoned CA2151927A1 (fr) | 1992-12-16 | 1993-11-12 | Cathepsine d, protease amyloidogene dans la maladie d'alzheimer |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPH08508464A (fr) |
CA (1) | CA2151927A1 (fr) |
WO (1) | WO1994013319A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977074A (en) * | 1993-10-01 | 1999-11-02 | Merrell Pharmaceuticals, Inc. | Inhibitors of β-amyloid protein production |
CA2191924A1 (fr) | 1995-12-05 | 1997-06-06 | Kevin Felsenstein | Derives de 5-amino-6-cyclohexyl-4-hydroxyhexanamide, inhibiteurs de la production de proteine .beta.-amyloide |
EP1039883A4 (fr) * | 1996-07-09 | 2001-09-26 | Keith A Crutcher | Methodes de traitement de maladies liees a l'apolipoproteine e |
US5703129A (en) * | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
GB9815163D0 (en) * | 1998-07-13 | 1998-09-09 | Brax Genomics Ltd | Compounds |
ES2318902T3 (es) * | 1998-09-24 | 2009-05-01 | PHARMACIA & UPJOHN COMPANY LLC | Secretasa en la enfermedad del alzheimer. |
AU3194900A (en) * | 1999-03-19 | 2000-10-09 | Yamanouchi Pharmaceutical Co., Ltd. | Method for screening cysteine protease inhibitor |
GB0008710D0 (en) * | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic compounds |
US6432944B1 (en) | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
JP2008100969A (ja) * | 2006-10-20 | 2008-05-01 | Tetsuhiro Niitome | 桑の葉抽出物を含むアルツハイマー病の予防または治療用の飲食物および医薬組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4650661A (en) * | 1982-09-15 | 1987-03-17 | Aktiebolaget Hassle | Enzyme inhibitors |
US5187153A (en) * | 1986-11-17 | 1993-02-16 | Scios Nova Inc. | Methods of treatment using Alzheimer's amyloid polypeptide derivatives |
US4963654A (en) * | 1989-02-13 | 1990-10-16 | Taisho Pharmaceutical Co., Ltd. | Peptide serine protease inhibitor |
WO1992003542A1 (fr) * | 1990-08-17 | 1992-03-05 | Boston University | PROTEASE PROVOQUANT UNE DEGRADATION ANORMALE DU PRECURSEUR DE PROTEINE-β D'AMYLOIDE |
DE4026614A1 (de) * | 1990-08-23 | 1992-02-27 | Bayer Ag | Phosphonopyrrolidin- und piperidin-haltige pseudopeptide vom statintyp, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel gegen retroviren |
-
1993
- 1993-11-12 WO PCT/US1993/010889 patent/WO1994013319A1/fr not_active Application Discontinuation
- 1993-11-12 JP JP6514167A patent/JPH08508464A/ja active Pending
- 1993-11-12 CA CA002151927A patent/CA2151927A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JPH08508464A (ja) | 1996-09-10 |
WO1994013319A1 (fr) | 1994-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6221645B1 (en) | β-secretase antibody | |
US5292652A (en) | Amyloidin protease and uses thereof | |
US7479372B2 (en) | Beta-secretase substrates and uses thereof | |
US5942400A (en) | Assays for detecting β-secretase | |
EP1842859B1 (fr) | Anticorps monoclone spécifique de peptide A4 beta | |
US6325989B1 (en) | Form of dipeptidylpeptidase IV (CD26) found in human serum | |
US5981208A (en) | Diagnostic assay for Alzheimer's disease based on the proteolysis of the amyloid precursor protein | |
JP2003503072A (ja) | 触媒的に活性な組換えメマプシンおよびその使用方法 | |
NO320067B1 (no) | In vitro fremgangsmate for registrering av prosessering av beta-amyloid forloper proteinet (betaAPP) i celler og opploselig fragment av beta-amyloid forloper protein i renset og isolert form. | |
US5968764A (en) | Glucose transporter vesicle aminopeptidase | |
WO1995013084A1 (fr) | Identification de la cathepsine d comme protease amyloïdogene de la maladie d'alzheimer | |
AU679675B2 (en) | Methods for detecting beta amyloid precursor protein processing enzymes | |
CA2151927A1 (fr) | Cathepsine d, protease amyloidogene dans la maladie d'alzheimer | |
US20030092629A1 (en) | Inhibitors of memapsin 2 and use thereof | |
AU785240B2 (en) | Novel bee venom polypeptides and methods of use thereof | |
US7189699B2 (en) | Peptides for the treatment of Alzheimer's disease and other β-amyloid protein fibrillogenesis disorders | |
AU5726494A (en) | Cathepsin d is an amyloidogenic protease in alzheimer's disease | |
AU7115094A (en) | Cathepsin d is an amyloidogenic protease in alzheimer's disease | |
NZ272218A (en) | Regulation of formation of beta-amyloid with a beta-amyloid precursor protease inhibitor | |
EP1496124A1 (fr) | Inhibiteurs de mémapsine 2 et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |